Detalhe da pesquisa
1.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474768
2.
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Gastroenterology
; 155(2): 479-489.e7, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29655834
3.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730009
4.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Eur Urol Oncol
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575409
5.
Primum non Nocere: How to ensure continuity of care and prevent cancer patients from being overlooked during the COVID- 19 pandemic.
Cancer Med
; 12(2): 1821-1828, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35754357
6.
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).
Diagnostics (Basel)
; 13(9)2023 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37174986
7.
Management of lung cancer patients during COVID-19 pandemic: dos, don'ts and don't knows.
Explor Target Antitumor Ther
; 3(3): 321-336, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045909
8.
Seminoma Retroperitoneal Relapse 23 Years After Surgery.
Oncol Ther
; 9(1): 239-245, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33606194
9.
Contrasting Fake News in Oncology: The First Declaration of Good Communication.
JCO Glob Oncol
; 7: 740-746, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019461
10.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Eur J Cancer
; 150: 224-231, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934059
11.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827906
12.
Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management.
Cancer Manag Res
; 12: 9363-9374, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33061625
13.
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management.
Ther Clin Risk Manag
; 16: 663-672, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32801723
14.
The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer.
Clin Med Insights Oncol
; 14: 1179554920936605, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32636693
15.
Gender Differences and Outcomes in Melanoma Patients.
Oncol Ther
; 8(1): 103-114, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700073
16.
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study.
Oncol Ther
; 8(1): 115-124, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700076
17.
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis.
Crit Rev Oncol Hematol
; 151: 102974, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416348
18.
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Expert Opin Ther Targets
; 24(9): 937-943, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662701
19.
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions.
J Thorac Dis
; 12(12): 7245-7256, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33447413
20.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077515